Particularly, in patients with KRAS-mutant lung adenocarcinoma, STK11/LKB1 alterations are significantly associated with PD-L1 negativity and promote resistance to PD-1 inhibitors (Skoulidis et al., 2018). The gene discussed is STK11; the disease is lung adenocarcinoma.